A genotype found to be associated with reduced cardiovascular events in a study of dalcetrapib wasn’t associated with benefit in a trial of fellow CETP inhibitor evacetrapib.
The physician-scientist draws the American Heart Association’s highest scientific honor for decades of pioneering research in multiple areas.
The recent landmark trial conclusively proved the inflammatory hypothesis of atherothrombosis. But it did a good deal more. Dr. Steven Nissen explains.
The story linking gut microbes, TMAO and heart disease has turned toward therapy interventions with the first demonstrated targeting of a gut microbial pathway to curb diet-induced heart disease.